The first domestic new crown special medicine is effective for "the worst strains"

"As a result that I just got yesterday, Anbawei's monoclonal anti -anti -anti -anti -anti -anti -combination therapy showed a good virus inhibitory effect on the new branches of the Omikon mutant BA.4 and BA.5." 7 On the 8th, the first self -developed newly -developed virus therapy drug Anbawei's monoclonal anti -anti -anti -anti -anti -anti -anti -anticipation combination therapy was held to hold a listing conference. Professor Lu Hongzhou, Dean of Shenzhen Third People's Hospital, introduced at the meeting. Pseudo -virus research shows that the drug only requires a very low antibody concentration (16.61 micrograms/ml) to inhibit 90%of the BA.4 or BA.5 strains to reach the effective standards specified by the FDA (US Food and Drug Administration) Essence

The new coronal virus is still mutating. As far as neutralized antibody drugs are concerned, the most worrying thing is that after the virus variation, the antibody combining site changes and the virus escapes.

In addition, in the past clinical treatment, Anbawei's monoclonal anti -anti -anti -anti -anti -combination therapy also showed good results. Zhong Nanshan, an academician of the Chinese Academy of Engineering, stated at the meeting that based on the observation of clinicians, the combined therapy could make the high virus load down rapidly within a relatively short time (2-3 days). The patients are very effective.

So, how can the first domestic new crown special medicine be "long -lasting"?

Best "antibody pair"

Because neutralized antibody drugs are designed for the specific target of virus S protein, when the new coronal virus mutates is mutated, the drug will be completely invalid if the drug targets is exactly mutated.

"Earlier, neutralized antibody drugs developed by multiple multinational pharmaceutical companies lost their inhibitory activity on Omikon's mutant strains and were stopped clinical use." Lu Hongzhou said, and the first domestic neutralized antibody drugs inhibit Omikh The tests were tested at the time of Rongjiezhu. Not only did they show the ability to suppress the new branch of Omikon Rong in in vitro experiments, but also in clinical practice. Inhibitory effect.

Why is the domestic neutralized antibody drugs that have gone through the "huge change" of the new coronal virus?

Zhang Linqi, the head of the R & D team and professor at the School of Medicine of Tsinghua University, introduced the trick at the meeting: Everyone used the "antibody pair" method to avoid escape from being escaped by the virus, but the "antibody against" was particular about the "antibody against". "Two antibodies must cooperate with each other and can play a combination of fists. For example, to identify the different positions of the virus." Zhang Linqi said that it was very tangled during the screening, but based on the refined research on the interaction of the entire virus and antibody, finally from 206 from 206 In a candidate antibody, the "antibody pair" that can coordinate with each other that can inhibit the virus and find the "best partner".

Several drug advantages

In terms of medication, the combined therapy has significant advantages in terms of effective time, medication time, and continuous effectiveness.

"The effect is very fast." Zhang Linqi introduced that by studying the best dose of dosage, the team made the two antibodies reaching a very high level within a few hours in the body, so the drug effect was very fast.

"Injection can be maintained for a long time in the body." Zhang Linqi said that because of many years of experience and lessons in antibody research and development, the team's special anti -antibody has optimized a series of optimizations, which has extended the half -life in the body by 3-4 times. Compared with small molecular drugs for 5-7 days of treatment, the neutralized antibody injection still maintains a sufficient concentration of killing the virus in the body 3 weeks after injection.

In addition, the use of the combined therapy is relatively loose. "The new coronal virus is more obvious in the early stage. The earlier the small molecule antiviral drugs, the better the effect. Generally, the positive use is detected within 5 days. We can still use these two antibody drugs within 6-10 days. Therefore, the scope of clinical adaptation of patients is relatively wide. "Lu Hongzhou said.

On the same day, Teng Shengbo Medicine and its holding company Teng Shenghua announced that its long -acting new crowns and antibodies with antibodies and Romi Siwei's combination therapy were listed on the commercialization of China. The combined therapy was approved by the State Drug Administration on December 8, 2021, and was included in the "New Coronary Virus Pneumonia Diagnosis Plan (Trial Ninth Edition)" in March 2022.

Source: Science and Technology Daily

- END -